Stockscreener 앱 받기
30.50
0.10%
-0.03
시간 외 거래:
30.50
전일 마감가:
$30.53
열려 있는:
$30.32
하루 거래량:
4.08M
Relative Volume:
1.56
시가총액:
$3.81B
수익:
$1.24B
순이익/손실:
$209.00M
주가수익비율:
18.37
EPS:
1.6605
순현금흐름:
$-94.86M
1주 성능:
-1.17%
1개월 성능:
-11.44%
6개월 성능:
+35.50%
1년 성능:
+206.53%
1일 변동 폭
$30.00
$30.99
1주일 범위
$30.00
$32.24
52주 변동 폭
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
명칭
Indivior Pharmaceuticals Inc
전화
804-379-1090
주소
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
30.50 | 3.82B | 1.24B | 209.00M | -94.86M | 1.6605 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program - MSN
Indivior Pharmaceuticals to report Q4 earnings: What's in the cards? - MSN
Indivior Issues $500 Million Convertible Senior Notes Offering - TipRanks
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior Pharmaceuticals Raises $500 Million Via 0.625% Convertible Notes Due 2031 - TradingView
Implied volatility surging for Indivior Pharmaceuticals stock options - MSN
Indivior Pharmaceuticals Survey Reveals Gaps in Medications for Opioid Use Disorder in U.S. Jails and Prisons - Quiver Quantitative
Indivior plans $400M convertible senior notes offering - MSN
Indivior plans $400 million convertible notes offering By Investing.com - Investing.com Nigeria
Does Indivior’s Upsized Convertible Notes and Buybacks Shift the Bull Case For Indivior (INDV)? - simplywall.st
How Indivior’s Upsized $450 Million Convertible Notes and Buybacks May Impact Indivior (INDV) Investors - Yahoo Finance
Indivior director Kingsley buys $29,953 in shares By Investing.com - Investing.com Nigeria
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 221% One Year Surge? - simplywall.st
Indivior prices $450 million convertible notes offering By Investing.com - Investing.com Australia
Insider Buying: Barbara Ryan Acquires Shares of Indivior Pharmac - GuruFocus
Indivior Pharmaceuticals prices upsized $450M convertible senior notes - MSN
INDV SEC FilingsIndivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital - AD HOC NEWS
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Indivior Prices Upsized Convertible Notes for Debt Refinancing - TipRanks
Indivior prices upsized $450M 0.625% convertible notes due 2031 - TradingView
Indivior (INDV) Upsizes Convertible Notes Offering to $450M - GuruFocus
Indivior Prices Upsized $450 Million Senior Notes Offering - marketscreener.com
Indivior Announces Proposed Convertible Senior Notes Offering - Sahm
Indivior Prices $450 Million Convertible Senior Notes Offering - National Today
Indivior (INDV) Plans $400 Million Convertible Notes Offering - GuruFocus
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewswire
Indivior plans $400 million convertible notes offering - Investing.com South Africa
Indivior prices $450 million convertible notes offering - Investing.com
Indivior Pharmaceuticals Announces Pricing of $450 Million Convertible Senior Notes Offering - Quiver Quantitative
Indivior proposes $400M convertible senior notes due 2031 to refinance debt, fund buybacks - TradingView
Indivior Announces $400 Million Convertible Notes and Buyback - TipRanks
Indivior stock falls after convertible notes offering announced - Investing.com
Indivior (Nasdaq: INDV) to issue $400M convertible notes and repay debt - Stock Titan
Indivior (NASDAQ: INDV) prices 0.625% convertible senior notes due 2031 - Stock Titan
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Indivior director Kingsley buys $29,953 in shares - Investing.com Australia
Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares - MarketBeat
Indivior (INDV) Study: Sublocade Reduces Healthcare Costs for OU - GuruFocus
New Study Shows Adherence to Monthly Injectable - GlobeNewswire
Ryan Barbara buys Indivior (INDV) shares worth $1,009 - Investing.com South Africa
Ryan Barbara buys Indivior (INDV) shares worth $1,009 By Investing.com - Investing.com Canada
Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV - MarketBeat
Indivior Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Earnings Growth And New US$400 Million Buyback - Sahm
Indivior Pharmaceuticals Inc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):